Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Autologous transplantation followed by maintenance vs maintenance alone in patients with MCL

Peter Riedell, MD, University of Chicago Medicine, Chicago, IL, explains the rationale and design of an ongoing Phase III study comparing consolidation with autologous transplantation followed by rituximab vs rituximab maintenance alone in patients with mantle cell lymphoma (MCL) in MRD-negative first complete remission (NCT03267433). This study aims to determine whether all patients with MCL benefit from stem cell transplantation (SCT) or if some patients could derive more benefit from other therapies. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

Disclosures

Consultant and/or advisory board member for AbbVie, Bayer, BeiGene, BMS, Janssen, Karyopharm, Kite Pharma/Gilead, Novartis, Nurix, and Takeda. Speaker for Kite Pharma/Gilead and he has received honoraria from Novartis. Research support from BMS, Calibr, CRISPR Therapeutics, Fate Therapeutics, Kite Pharma/Gilead, MorphoSys, Novartis, Tessa Therapeutics, and Xencor.